Drug Trial Radar · NCT03535558
Fluoroquinolone Associated Disability
Last checked: Nov 19, 2026Latest source record: Jan 29, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
239,306
Actual
Start
May 17, 2018
Primary completion
Dec 31, 2018
Study completion Dec 31, 2018
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- May 24, 2018
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to: 1) describe drug utilization for Fluoroquinolone(FQ), Azithromycin (AZ) and Sulfamethoxazole/Trimethoprim(ST) in the entire Truven MarketScan Commercial Claims and Encounters database (CCAE) database, and specifically among individuals in the Health and Productivity Management (HPM) during the observation period; 2) describe the rate of disability associated with 2 or more System Organ Class adverse events (SOC AEs) and exposure to FQs for several acute, uncomplicated indications; and 3) compare the rates of disability for 2 or more SOC AEs and exposure to FQs and AZ/ST for the same indications.
Conditions
- Bronchitis
- Sinusitis
- Urinary Tract Infections
Interventions
Fluoroquinolone (FQ)Drug
Participants exposed to an oral FQ will be observed. The oral FQ included are Levofloxacin, Ciprofloxacin, Moxifloxacin, Ofloxacin, Gemifloxacin. Participants will not receive any intervention as a part of this study.
Azithromycin (AZ)Drug
Participants exposed to an oral AZ will be observed. Participants will not receive any intervention as a part of this study.
Sulfamethoxazole/Trimethoprim (ST) Fixed Dose CombinationDrug
Participants exposed to an oral ST will be observed. Participants will not receive any intervention as a part of this study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Disability in Temporal ProximityTime frame: Up to 120 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Janssen Investigative Site
Titusville, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.